Vicuron Pharmaceuticals Announces Departure From Board of Directors of Ubaldo Livolsi and Francesco Parenti

Vicuron Pharmaceuticals Announces Departure From Board of
Directors of Ubaldo Livolsi and Francesco Parenti 


KING OF PRUSSIA, Pa., July 2  /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals
Inc. (Nasdaq: MICU; Nuovo Mercato: MICU), today announced the resignation of
Ubaldo Livolsi, Ph.D., and retirement of Francesco Parenti, Ph.D., from the
company's board of directors.

"We are grateful to Drs. Livolsi and Parenti for their work and contributions,
particularly over the last year in helping to guide the successful merger
between Versicor and BioSearch Italia," said George F. Horner III, Vicuron's
president and chief executive officer. "As true pioneers in the field, their
knowledge, experience and insight were instrumental in the building of our
company."

About Vicuron

Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients in North America and major countries in Europe. The company's lead
product, anidulafungin is under review by the U.S. Food and Drug
Administration. The company's other lead product, dalbavancin, a novel
intravenous antibiotic for the treatment of serious Gram-positive infections,
is in Phase III clinical trials. The company's versatile research engine
integrates industry-leading expertise in functional genomics, natural products
discovery, mechanism-based drug design and combinatorial and medicinal
chemistry. These approaches are yielding promising novel and next-generation
compounds, many of which are in the later stages of preclinical development. In
addition, the company has research and development collaborations with leading
pharmaceutical companies, such as Pfizer and Novartis.

Forward-Looking Statements

This news release contains forward-looking statements that predict or describe
future events or trends. The matters described in these forward- looking
statements are subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond Vicuron's control. Vicuron
faces many risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be delayed,
that the timing of the filing of any new drug application might be delayed,
that subsequent clinical trials might indicate that a product candidate is
unsafe or ineffective, that any filed new drug application may not be approved,
that ongoing proprietary and collaborative research might not occur or yield
useful results, that a third party may not be willing to license our product
candidates on terms acceptable to us or at all, that competitors might develop
superior substitutes for their products or market them more effectively, that a
sales force may not be developed as contemplated and that one or more of its
product candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is subject. Because
of those risks, Vicuron's actual results, performance or achievements may
differ materially from the results, performance or achievements contemplated by
its forward-looking statement. The information set forth in this news release
represents management's current expectations and intentions. Vicuron assumes no
responsibility to issue updates to the forward-looking matters discussed in
this news release. 

DATASOURCE: Vicuron Pharmaceuticals Inc.



CONTACT:  Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc.,

[phone], or ; or Hala Bashir of WeissCom

Partners, [phone], or , for Vicuron Pharmaceuticals

Inc.; or Aline Schimmel of Burns McClellan, [phone], or

, for Vicuron Pharmaceuticals Inc.



Web site:  http://www.vicuron.com/ 

Copyright